"AOH1996 is a very unremarkable-looking molecule - to be honest, it looks like the sort of stuff that you used to see in old combinatorial chemistry libraries in the late 90s and early 2000s, a couple of aryl-rich groups strung together with amide bonds."
https://www.science.org/content/blog-post/new-mode-cancer-tr...
“I hope that human cancers will prove vulnerable to this new mode of attack in the clinic, and that they are not able to mutate around it with new forms of caPCNA too quickly, either.”
Even if this does prove effective in humans, eventually cancer cell defenses will evolve to get around it.
Cancer becomes tolerant to drugs separately for each patient. I.e. initially it isn't resistant, but the drug used on a patient puts evolutionary pressure on the cancer to work around the drug. What this means is that people have more months or years to live, which is great. (I am not a doctor).
The ABVD regime starts with the same baseline on all hodgkin's lymphoma patients, and 'cures' cancer permanently in quite a large number of them.